Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Ordinary shares, par value 0.002 GBP per share
-
Shares outstanding
-
147M
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
128M
-
Shares change
-
+4.8M
-
Total reported value, excl. options
-
$3.11B
-
Value change
-
+$148M
-
Put/Call ratio
-
0.6
-
Number of buys
-
57
-
Number of sells
-
-69
-
Price
-
$24.25
Significant Holders of Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) as of Q3 2025
159 filings reported holding CNTA - Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share as of Q3 2025.
Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 128M shares
of 147M outstanding shares and own 87.48% of the company stock.
Largest 10 shareholders include Medicxi Ventures Management (Jersey) Ltd (20M shares), Avoro Capital Advisors LLC (10.8M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (10M shares), Index Venture Life Associates VI Ltd (9.96M shares), GENERAL ATLANTIC, L.P. (9.68M shares), FMR LLC (6.28M shares), JANUS HENDERSON GROUP PLC (5.41M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.8M shares), FARALLON CAPITAL MANAGEMENT LLC (4.33M shares), and First Light Asset Management, LLC (3.64M shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.